Colorectal disorders:

Indications for: APRISO

Maintenance of remission of ulcerative colitis (UC) in adults.

Adult Dosage:

Swallow whole. 1.5g once daily in the AM.

Children Dosage:

Not established.

APRISO Warnings/Precautions:

Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Phenylketonuria. Renal or hepatic impairment. History of renal disease. Assess renal function prior to and periodically during therapy. Discontinue if renal function deteriorates while on therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.

APRISO Classification:


APRISO Interactions:

Avoid concomitant antacids. Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine.

Adverse Reactions:

Headache, diarrhea, upper abdominal pain, nausea, nasopharyngitis; renal impairment, hypersensitivity reactions, mesalamine-induced acute intolerance syndrome (eg, cramping, abdominal pain, bloody diarrhea, fever, headache, rash), severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP).



Drug Elimination:

Renal. Half-life: 9–10 hours.

Generic Drug Availability:


How Supplied: